The EPO published patent application EP4061368A1 titled 'Methods of Administering Voxelotor' filed by Global Blood Therapeutics, Inc. Voxelotor is a hemoglobin S polymerization inhibitor used for treating sickle cell disease. The application covers voxelotor formulations and dosing methods under IPC classifications A61K 31/4439 and A61P 7/00, designated for protection in all European patent convention states including Germany, France, UK, Italy, Spain, and 29 other member countries.

Pharmaceutical companies and generic drug manufacturers should review this publication for freedom-to-operate assessments and potential licensing considerations. Competitors developing competing sickle cell treatments should analyze the claims for potential design-around opportunities. The 18-month publication period from filing means the application details are now publicly accessible for review. No immediate compliance action is required as patent applications impose no regulatory obligations on third parties.